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Abstract The 5-HT7 (5-hydroxytryptamine 7, serotonin
7) receptor is one of the most recently identified members
of the serotonin receptor family. Pharmacological tools,
including selective antagonists and, more recently, ago-
nists, along with 5-HT7 receptor (5-HT7R) knock-out mice
have revealed the involvement of this receptor in central
nervous system processes. Its well-established role in
controlling body temperature and regulating sleep and
circadian rhythms has implicated this receptor in mood
disorders. Thus, the 5-HT7R has gained much attention as a
possible target for the treatment of depression. Although
preclinical data support the antidepressant-like actions of
5-HT7R antagonists, their clinical efficacy has not been yet
established. Other evidence has implicated the 5-HT7R in
learning and memory. Preclinical findings suggest that
blockade of this receptor may be beneficial against
schizophrenia-like cognitive deficits. Other possible indi-
cations include nociception, epilepsy, migraine, autism
spectrum disorders, and Rett Syndrome. However, the
question is whether the beneficial effects may be achieved
by activation or blockade of 5-HT7Rs. Hence, this review
briefly summarises the recent findings on the role of
5-HT7Rs and their ligands in CNS disorders.
Key Points
5-hydroxytryptamine 7 (5-HT7) receptors not only
play a physiological role in the regulation of the
central nervous system (CNS) but also may be
involved in pathological processes.
Thus, these receptors represent a potential
therapeutic target for treating CNS disorders.
However, whether therapeutic efficacy can be
achieved via activation or blockade of the 5-HT7
receptor remains uncertain.
1 Introduction
The 5-hydroxytryptamine 7 receptor (5-HT7R) was cloned
in 1993 by independent laboratories [1–3]. To date, several
splice variants have been described [4, 5], but the only
functional difference that has been reported so far is a
differential pattern of receptor internalisation displayed by
the human 5-HT7R (d) isoform [6]. This receptor, be-
longing to the G-protein-coupled receptor (GPCR) super-
family, is positively coupled to adenylate cyclase through
the stimulatory Gas proteins, and its activation results in an
increase in cyclic adenosine monophosphate (cAMP). In
addition, it has been recently demonstrated that the 5-HT7R
interacts not only with the Gas but also with Ga12 proteins
[7]. The dynamic palmitoylation can represent a molecular
mechanism responsible for selective Gas- or Ga12-medi-
ated signalling [8]. Recent evidence suggests that 5-HT7R/
Ga12 signalling in the hippocampus undergoes strong de-
velopmental regulation with a pronounced transient
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increase during early postnatal stages and may represent a
molecular mechanism by which serotonin specifically
modulates the formation of initial neuronal networks [9].
The pharmacology and signal transductions of 5-HT7Rs
may be even more complicated, as it has been recently
demonstrated that these receptors may form homodimers
[10]; the heterodimerisation with 5-HT1AR has also been
reported [11].
2 Ligands of 5-HT7 Receptors
Several 5-HT7R antagonists are available, including the
nonselective antagonist DR-4004 [12] and several selective
antagonists such as SB-258719 [13], SB-269970 [14], SB-
656104 [15] and JNJ-18038683 [16] (Table 1). In the ab-
sence of selective agonists of 5-HT7Rs, unselective com-
pounds such as 5-carboxamidotryptamine or 8-hydroxy-2-
(dipropylamino)tetralin (8-OH-DPAT) (5-HT1A/7R ago-
nist) have often been used. More recently, various selective
5-HT7R agonists have been identified (reviewed in detail
by Di Pilato et al. [17]), including AS-19 [18], LP-44 [19],
LP-12 [19], LP-211 [20], and E-55888 [18] (Table 1). The
purpose of this review is to summarize existing data on the
effects of 5-HT7R ligands in animal models of central
nervous system (CNS) disorders. When available, clinical
data are also discussed.
3 Depression
A converging body of evidence has shown that the selec-
tive blockade of 5-HT7Rs displays an antidepressant-like
activity in commonly used preclinical tasks, i.e. in the tail
suspension test (TST) in mice as well as in the forced swim
test (FST) in both mice and rats [16, 21–26]. Specifically,
5-HT7R knock-out (KO) mice showed an antidepressant-
like behavioural profile as revealed by reduced immobility
in the FST and TST [21–23]. In line with genetic inacti-
vation effects, the pharmacological blockade of 5-HT7Rs
by the selective antagonist SB-269970 also exerted an-
tidepressant-like activities in the TST [22, 24, 25] as well
as in the FST in both mice [22, 25] and rats [26]. JNJ-
18038683 was also effective in the mouse TST [16].
Moreover, the efficacy of SB-269970 was also assessed in
the olfactory bulbectomy paradigm, which is considered a
behavioural model of agitated depression [27]. Interest-
ingly, SB-269970 produced a faster antidepressant-like
response than the commonly prescribed selective serotonin
reuptake inhibitor (SSRI) antidepressant fluoxetine.
In addition to exerting a distinct antidepressant-like
action, the blockade of 5-HT7Rs may also augment the
behavioural effects of antidepressant drugs. For example,
SB-269970, administered at a dose not exerting a sig-
nificant antidepressant effect, enhanced the action of sub-
effective doses of antidepressant drugs, including the SSRI
citalopram, in the TST and FST in mice [23, 24, 28].
5-HT7R may also represent a clinically relevant target
for the treatment of depression. It has been suggested that
the clinically established antidepressant effect of certain
antipsychotics, such as amisulpride, aripiprazole or lurasi-
done, is most likely mediated by the 5-HT7R [23, 29, 30].
In fact, functional 5-HT7Rs were required to reveal the
antidepressant-like effects of those drugs in the TST and
FST in mice [23, 29, 30]. Moreover, one clinical study
evaluated the efficacy of JNJ-18038683, a selective an-
tagonist of 5-HT7Rs, as an antidepressant in patients with
major depressive disorder [16]. There was no statistically
significant improvement over a placebo on the Mont-
gomery-A˚sberg Depression Rating Scale (MADRS) after
either JNJ-18038683 or escitalopram administration. Thus,
due to a lack of assay sensitivity, the interpretation of these
results is inconclusive.
4 Stress
Prolonged stress is a major risk factor for depression, and
stress-based animal models represent a useful instrument
for mimicking depressive-like symptomatology [31]. It has
been proposed that the modulatory role for serotonin in the
stress-evoked hypothalamic-pituitary-adrenal axis response
may involve 5-HT7Rs [32]. Recent data suggest that
chronic restraint stress-induced endocrine disruption may
be associated with the increased function and expression of
5-HT7Rs [33]. Consequently, pharmacological blockade of
adrenocortical 5-HT7Rs could be of therapeutic benefit for
overcoming endocrine disruption in stress-related diseases.
Moreover, 5-HT7Rs may also be involved in the response
of neural circuits to repeated stress. Repeated corticos-
terone administration, a model known to mimic some
aspects of stress exposure, increased the reactivity of rat
CA3 hippocampal circuitry to the activation of 5-HT7Rs
[34]. Moreover, the selective 5-HT7R antagonist SB-
269970 counteracted restraint stress-induced attenuation of
long-term potentiation in the rat frontal cortex [35]. It has
also been demonstrated that exposure to chronic mild stress
evokes up-regulation of 5-HT7R messenger RNA (mRNA)
in the rat hippocampus and hypothalamus, and these
changes were counteracted by the antidepressant fluoxetine
[36]. In addition, data from our laboratory indicate that the
administration of SB-269970 reversed the stress-induced
cognitive deficit in rats [37]. In line with data demon-
strating that selective blockade of 5-HT7Rs augmented the
behavioural effects of antidepressants, SB-269970, ad-
ministered at an inactive dose, enhanced the pro-cognitive
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SB-258719: 3-methyl-N-[(1 R)-1-methyl-3-(4-methyl-1-piperidinyl)propyl]-N-methylbenzenesulfonamide [13]
Epilepsy Antiepileptic activity in the WAG/Rij rat model of absence epilepsy 10 [93]
SB-258741: R-(?)-1-(toluene-3-sulfonyl)-2-[2-(4-methylpiperidin-1-yl)ethyl]-pyrrolidine [110]
Schizophrenia Reversal of amphetamine-induced hyperactivity 2.3–9.1 [75]
Normalisation of PCP-disrupted PPI 2.3–9.1 [75]
SB-269970: (2 R)-1-[(3-hydroxyphenyl)sulfonyl]-2-[2-(4-methyl-1-piperidinyl)ethyl]pyrrolidine [14, 110]
Depression Antidepressant-like effect in the FST and TST in mice 10 [22]
Antidepressant-like effect in the TST in mice 3–30 [24]
Antidepressant-like effect in the FST and TST in mice 5–10 [25]
Antidepressant-like effect in the FST in rats 1.25–2.5 [26]
Antidepressant-like effect in olfactory bulbectomised rats 2 [27]
Sleep REM sleep-suppressive effect in rats 10 [24]
REM sleep-suppressive effect in rats 10–20 [39]
Circadian
rhythms
Blockade of 8-OH-DPAT-induced a phase advance in the rat SCN slices 0.01 lM [44]
Anxiety Anxiolytic-like effects in the Vogel drinking test and the elevated plus-maze test in rats as well
as in the four-plate test in mice
0.5–1 [25]
OCD Reduced marble burying in mice 10 [53]
Cognition Improvement of reference memory in a radial arm maze task in rats 1 [67]
Deficit in novel location test in mice 10 [56]
Improvement of cognitive flexibility in the ASST in rats 1 [37]
Improvement of object recognition memory in the NORT in rats 30 [58]
Deficits in object recognition memory in the NORT in mice 3–10 [59]
Schizophrenia Reversal of amphetamine- and ketamine-induced hyperactivity in mice 10–30 [74]
Reversal of PCP-induced hyperactivity in rats 30 [58]
Reversal of the amphetamine-induced PPI deficits in mice 30 [74]
Reversal of MK-801-induced deficits in an autoshaping Pavlovian instrumental learning task in
rats
3–10 [81]
Reversal of intra-prefrontal ketamine–induced deficits in rats’ autoshaping Pavlovian
instrumental learning task
1 lg [82]
Reversal of the PCP-induced deficits in reversal learning 3–10 [79]
Reversal of the MK-801-induced impairment in working memory on a rat delayed non-
matching to position task
10 [80]
Reversal of PCP-induced deficits in the NORT in rats 1 [83]
Reversal of ketamine-induced deficits in the NORT in rats 1 [77]
Reversal of ketamine-induced cognitive inflexibility on the ASST in rats 1 [77]
Reversal of ketamine-induced social withdrawal in rats 1 [77]
Epilepsy Antiepileptic activity in a pilocarpine-induced rat model of temporal lobe epilepsy 10 [94]
Migraine Inhibition the 5-CT-induced dilatation in the middle meningeal artery in rats 1 [100]
Reduction of neurogenic dural vasodilation in rats 5–10 [101]
SB-656104: 6-[(R)-2-[2-[4-(4-chlorophenoxy)-piperidin-1-yl]-ethyl]-pyrrolidine-1-sulfonyl]-1 H-indole [15]
Sleep REM sleep-suppressive effect in rats 30 [15]
Schizophrenia Reversal of MK-801-induced learning and memory impairments in the passive avoidance and
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efficacy of an inactive dose of the SSRI escitalopram [37].
Thus, the stress-evoked enhancement of 5-HT7R-mediated
responses or up-regulation of their expression may pur-
portedly account for the efficacy of the 5-HT7R antagonist
in ameliorating stress-induced abnormalities. Nevertheless,
it should be noted that the relation between stress, gluco-
corticoids and 5-HT7R expression and function seems to be
far more complex [32].
5 Sleep and Circadian Rhythm Regulation
The role for the 5-HT7Rs in mood disorders is closely
linked to the regulation of sleep and circadian rhythms
[38]. Similar to the actions of antidepressant drugs, the
blockade of 5-HT7Rs was shown to alter rapid eye move-
ment (REM) sleep parameters in the opposite direction to
the abnormalities found in depression patients. Specifical-
ly, 5-HT7R KO mice spent less time in and demonstrated
less frequent episodes of REM sleep [22]. Similar changes
in REM sleep patterns were demonstrated after adminis-
tration of 5-HT7R antagonists, including SB-269970, SB-
656104 and JNJ-18038683 [24, 39]. Moreover, both ge-
netic inactivation and pharmacological blockade aug-
mented the effects of SSRIs on REM sleep suppression [24,
40]. The effect of a 5-HT7R blockade on REM sleep
translates from rodent to humans, as JNJ-18038683 was
also found to increase REM latency and decrease REM
sleep duration in healthy volunteers [16]. Of note is the





Depression Antidepressant-like effect in the TST in mice 0.3–1 [16]
Sleep REM sleep-suppressive effect in rats 1–10 [16]
REM sleep-suppressive effect in healthy human volunteers 20 mg [16]
Circadian
rhythms
Blockade of 8-OH-DPAT–induced and photic phase shifts of wheel running activity in mice 10 [45]
5-HT7R agonists
AS-19: [(2 S)-(?)-5-(1,3,5-trimethylpyrazol-4-yl)-2-(dimethylamino)tetralin] [18]
Cognition Improvement of long-term memory but impairment of short-term memory in an autoshaping




Shortened the period length of PER2 bioluminescence in explants of SCN from PER2::LUC
mice
0.01–0.1 lM [47]
Pain Reversal of capsaicin-induced mechanical hypersensitivity in mice 3–10 [18]
Hyperalgesic effects in a mice model of nerve injury 0.1–10 [88]
Hyperalgesic effects in a rat model of nerve injury 2.5–10 [89]
Reversal of thermal hyperalgesia in streptozotocin-induced experimental diabetes in mice 10 [90]
Epilepsy Pro-epileptic activity in a pilocarpine-induced rat model of temporal lobe epilepsy 10 [94]
Migraine Increase in neurogenic dural vasodilation in rats 5–10 [101]
LP-211: N-(4-cyanophenylmethyl)-4-(2-diphenyl)-1-piperazinehexanamide] [20]
Sleep REM sleep-suppressive effect in rats 5–10 [41]
Circadian
rhythms
Induction of phase advance in mice 0.25 [46]
Anxiety Anxiolytic-like effects in the black and white box test and the dark/light test in mice 0.25 [46]
Cognition Improvement of long-term memory in an autoshaping Pavlovian/instrumental learning task 1 [64]
Rett syndrome Reversal of anxiety-related behaviour in a light/dark test, motor performance in a Dowel test
and memory deficits in the novelty preference task in a mice model of the Rett syndrome
0.25 [99]
E-55888: dimethyl-[2-[3-(1,3,5-trimethyl-1 H-pyrazol-4-yl)-phenyl]-ethyl]amine] [18]
Pain Reversal of capsaicin-induced mechanical hypersensitivity in mice 3–10 [18]
Increase of the analgesic potency of morphine 10 [111]
Hyperalgesic effects in a rat model of nerve injury 10 [89]
Only studies demonstrating efficacies (or impairing effects) are included
ASST attentional set-shifting task, FST forced swim test, NORT novel object recognition test, OCD obsessive-compulsive disorder, PCP
phencyclidine, PPI prepulse inhibition, REM rapid eye movement, SCN suprachiasmatic nuclei, TST tail suspension test, 5-CT
5-carboxamidotryptamine
a Doses are mg/kg unless otherwise indicated
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suppressed REM sleep [41]. It has been proposed that ac-
tivation of 5-HT7Rs expressed by c-aminobutyric acid
(GABA)-ergic interneurons decreases the activity of REM
sleep-promoting cholinergic neurons in the laterodorsal
and pedunculopontine tegmental (LDT/PPT) nuclei and
reduces REM sleep (reviewed by Monti and Jantos [38]).
On the other hand, suppression of REM sleep by 5-HT7R
antagonists may involve the reduction of GABA-induced
inhibition of serotonergic cells that leads to the increase of
5-HT release at postsynaptic sites critical for REM sleep
occurrence, including the LDT/PPT nuclei [39].
5-HT7Rs have also been implicated in the regulation of
the mammalian circadian clock located in the suprachias-
matic nuclei (SCN). In vitro and in vivo studies have
demonstrated that 8-OH-DPAT-induced non-photic phase
resetting was mediated by the 5-HT7R, as the shift was
blocked by genetic inactivation or antagonists of those
receptors, including SB-269970, DR-4004 and JNJ-
18038683 [21, 42–45]. In line with these data, a selective
agonist of 5-HT7Rs, LP-211, induced a phase advancement
on spontaneous circadian rhythm in mice [46]. Moreover,
another 5-HT7R agonist, AS19, shortened the period length
of PER2 bioluminescence in explants of SCN from
PER2::LUC mice genetically modified to report changes in
the expression of a key clock protein [47]. This reduction
was blocked by SB-269970, a selective 5-HT7R antagonist.
The 5-HT7R is probably also involved in 5-HT-medi-
ated suppression of photic activation of the SCN [48].
However, a 5-HT7R agonist, AS-19, failed to inhibit light-
induced phase shifts [49]. The lack of effect may be
ascribed to the low efficacy of the tested compound [50].
It has also been suggested that a multimodal approach
based on a combination of SSRIs and 5-HT7R antagonists
may be beneficial in treating patients suffering from poor
circadian rhythm synchrony. In rodent models, the com-
bination of escitalopram and SB-269970 produced a
greater impact on circadian rhythms than that observed
with either agent alone [47]. In this study, combination of
inactive doses of escitalopram (2.5–10 mg/kg) and SB-
269970 (10–30 mg/kg) produced robust phase delays in
rats given access to running wheels. In line with these data,
vortioxetine, the SSRI exhibiting antagonistic affinity for
5-HT7Rs, produced an increase in circadian period length
in tissue explants from the SCN of PER2::LUC mice and
induced a phase delay in wheel-running behaviour in rats,
and this effect was blocked by AS19 [51].
6 Anxiety
In contrast to the well-established role for 5-HT7Rs in
depression, their involvement in the regulation of anxiety-
like behaviours is less consistent. No differences in assays
sensitive to anxiety states, that is, in the elevated plus maze
or light/dark transfer test, were observed between 5-HT7R
KO mice and wild-type (WT) controls [21, 52]. On the
other hand, SB-269970 exerted specific anti-anxiety-like
effects in the Vogel conflict test and the elevated plus maze
test in rats, as well as in the four-plate test in mice [25].
Moreover, SB-269970 reduced marble burying in mice, a
behaviour linked to obsessive-compulsive disorder and
anxiety [53]. Nevertheless, the compound’s efficacy in this
test probably reflects antidepressant-like activity. It has
also been reported recently that LP-211, an agonist of
5-HT7Rs, reduces anxiety-like behaviour in the black and
white box test and the dark/light test in mice [46]. More-
over, rats chronically treated during adolescence with LP-
211 showed reduced anxiety-related behaviour in adult-
hood [54].
7 Cognition
It has been demonstrated that the 5-HT7R is involved in
hippocampal-dependent cognitive processes (reviewed by
Roberts and Hedlund [55]). Accordingly, 5-HT7R KO mice
demonstrated impairments of contextual hippocampal-de-
pendent learning and displayed decreased long-term sy-
naptic plasticity within the CA1 region of the hippocampus
[52]. Moreover, hippocampus-associated spatial memory
deficits in the novel location test were demonstrated in
mice with either genetic or pharmacological inactivation of
5-HT7Rs [56]. Data from the Barnes maze test suggested
the impaired ability of 5-HT7 KO mice to utilise hip-
pocampal-dependent allocentric memory [56]. Interesting-
ly, it has been hypothesised that the decrease in the
hippocampal expression of 5-HT7R may underlie age-re-
lated deficits in allocentric spatial navigation [57].
The role of 5-HT7R was also evaluated in the novel
object recognition test (NORT). 5-HT7R KO mice did not
differ in their ability to discriminate a novel object from the
WT mice [56], whereas SB-269970 exerted no effect or
even improved recognition memory when administered
before the acquisition trial [56, 58]. On the other hand, SB-
269970 was shown to induce a NORT deficit when ad-
ministered during the consolidation phase in mice [59]. At
the same time, the improvement was noted after 5-HT7R
activation. Thus, it seems likely that 5-HT7R may play a
different role in the acquisition and consolidation of
recognition memory. Moreover, changes in the expression
of 5-HT7R may underlie novelty-seeking behaviour in rats
that in turn also affects their ability to discriminate objects
[60, 61].
In an autoshaping Pavlovian/instrumental learning task,
AS19 impaired short-term memory (STM) but improved
long-term memory (LTM) [62, 63]. Another 5-HT7 agonist,
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LP-211, did not affect STM, but it improved LTM [64],
(reviewed in detail by Meneses [65]). The pro-cognitive
actions of either AS19 or LP-211 were blocked by the
5-HT7R antagonist SB-269970. The 5-HT7R agonists LP-
44 and AS19 failed to facilitate emotional memory in the
passive avoidance task in mice [50]. However, the lack of
effect was ascribed to the low efficacy of LP-44 and AS19
for stimulating protein phosphorylation of 5-HT7R-acti-
vated signalling cascades. Data from our laboratory indi-
cate that AS19 also did not affect rats’ performance on the
attentional set-shifting task (ASST) [66]. Conversely, SB-
269970 (1 mg/kg) enhanced cognitive flexibility on the
ASST. Moreover, SB-269970 (1 mg/kg) was demonstrated
to improve reference, but not working, memory as assessed
in a radial arm maze task [67]. It might be concluded that
increasing the task complexity allows for revealing the pro-
cognitive effects of 5-HT7R blockade.
Although the role of 5-HT7Rs in modulating cognitive
processes under physiological conditions is not fully
understood [55, 65, 68, 69], recent reports suggest the
efficacy of 5-HT7R ligands in overcoming cognitive
impairments in disease models (described below).
8 Schizophrenia
A possible role for 5-HT7R s in the pathophysiology of
schizophrenia was suggested by post mortem studies that
demonstrated marked reductions in the level of 5-HT7Rs in
the prefrontal cortex of schizophrenia patients [70, 71].
Moreover, a genetic polymorphism study found a positive
association between the 5-HT7R gene and schizophrenia
[72].
Thus, 5-HT7R antagonists have been evaluated in ani-
mal models predictive of antipsychotic-like activity, based
on the administration of amphetamine or antagonists of N-
methyl-D aspartic acid (NMDA) receptors. Antagonists of
the NMDA receptors, such as phencyclidine (PCP), ke-
tamine or dizocilpine, may evoke not only behaviours re-
flecting positive symptoms (e.g. hyperactivity) but also
negative symptoms (e.g. social withdrawal) and cognitive
impairments [73].
The 5-HT7R antagonist SB-269970 significantly
blocked amphetamine-, PCP- and ketamine-induced hy-
peractivity in rats and mice [58, 74]. Another 5-HT7R
antagonist, SB-258741, also reversed amphetamine-in-
duced hyperactivity but reduced motility of rats at similar
doses [75]. Schizophrenic patients also suffer from distur-
bances in information processing, reflected as a deficient
sensorimotor gating, which may contribute to the cognitive
deficits that characterise this disorder [76]. Thus, several
studies assessed the effects of a 5-HT7R antagonist on an
operational measure of sensorimotor gating, i.e. prepulse
inhibition (PPI) of the startle reflex. Accordingly, SB-
269970 did not reverse the deficits in PPI evoked by ke-
tamine in rats [77] and mice [74] or by PCP in rats and
mice [78]. On the other hand, SB-269970 blocked the
amphetamine-induced PPI deficits in mice [74]. However,
5-HT7Rs may play a partial role in the glutamatergic PPI
model, as 5-HT7R KO mice were less prone to the PCP-
induced disruption of PPI than WT mice [78]. In addition,
another 5-HT7R antagonist, SB-258741, normalised PCP-
disrupted PPI but was ineffective in the amphetamine-
based model [75].
Pro-cognitive effects of 5-HT7R antagonists in animal
models of schizophrenia have been supported by several
studies. Specifically, deficits of prefrontal cortex functions,
a core feature of schizophrenia, have been ameliorated by
the blockade of 5-HT7Rs. Accordingly, SB-269970 at-
tenuated the PCP-induced deficits in reversal learning [79],
the dizocilpine-induced impairment in working memory as
assessed in a delayed non-matching to position task in rats
[80] and ketamine-induced cognitive inflexibility on the
ASST in rats in our hands [77]. SB-269970 also reversed
memory deficits demonstrated in an autoshaping Pavlovian
instrumental learning task in rats after systemic adminis-
tration of dizocilpine [81] or after an intra-prefrontal in-
fusion of ketamine [82]. The compound was also effective
against ketamine- and PCP-induced deficits in the NORT
in rats [77, 83]. Moreover, another antagonist of 5-HT7Rs,
SB-656104-A, reversed dizocilpine-induced learning and
memory impairments in the passive avoidance and Morris
water maze tests in rats [84].
The pharmacological blockade of 5-HT7Rs may also
have therapeutic implications for the treatment of negative
symptoms in schizophrenia. Although SB-25874 had no
beneficial effects on PCP-evoked deficits in social inter-
actions [75], SB-269970 ameliorated ketamine-induced
social withdrawal in rats [77].
Experimental data suggest the role of 5-HT7R an-
tagonism in the pro-cognitive actions of the antipsychotic
drugs amisulpride and lurasidone. Co-treatment with the
5-HT7R agonist AS19 reversed the abilities of amisulpride
and lurasidone to ameliorate the PCP-induced deficits in
the NORT in rats [83] as well as blocked the attenuating
effects of lurasidone on the MK-801-induced deficits in the
rat passive avoidance test [85]. The amisulpride-induced
enhancement of set-shifting ability was also blocked by
AS19 [66]. Additionally, the antagonism of 5-HT7Rs may
contribute to the mechanisms underlying the pro-social
action of amisulpride in rats [86]. It cannot be excluded
that the 5-HT7R may be involved in pro-cognitive effects
of other antipsychotic drugs (as for example clozapine) that
also possess high affinities for the 5-HT7R [87].
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9 Pain
Several preclinical findings support the utility of 5-HT7R
agonists in treating neuropathic pain. Accordingly, AS19
and E-55888 reversed mechanical hypersensitivity induced
by capsaicin in mice, a model predictive of the anti-noci-
ceptive action of analgesics in neuropathic pain [18].
Moreover, activation of 5-HT7Rs also reduced the nerve
injury-evoked mechanical and thermal hyperalgesia in a
model of sciatic nerve ligation in mice [88] and rats [89].
This approach may also be effective in treating diabetic
neuropathic pain, as AS19 reduced thermal hyperalgesia in
streptozotocin-induced experimental diabetes in mice [90].
However, the role for 5-HT7R in modulation of pain
seems to be quite complex (reviewed by Viguier et al.
[91]). Indeed, it has been demonstrated that under sensi-
tising neuropathic conditions, activation of 5-HT7Rs exerts
anti-nociceptive effects at the level of the spinal cord but
pro-nociceptive effects in the periphery [92]. However,
after systemic administration of 5-HT7R agonists, the anti-
nociceptive effect mediated by central 5-HT7Rs seems to
predominate. Moreover, the effects of 5-HT7R agonists
may be different in neuropathic versus intact healthy ani-
mals. For example, AS19 exerted a pro-nociceptive action
in healthy rats but alleviated nerve injury-evoked hyper-
algesia [91].
10 Epilepsy
The 5-HT7R has also been linked to seizure activity. The
5-HT7R antagonist SB-258719 was effective in reducing
spontaneous epileptic activity in the WAG/Rij rat model of
absence epilepsy [93]. In pilocarpine-induced rat models of
temporal lobe epilepsy, the 5-HT7R antagonist SB-269970
also reduced the number of seizures [94]. The opposite
effect was demonstrated by the 5-HT7R agonist AS19 in
that model. In contrast to pharmacological data, a deletion
of the 5-HT7R decreased the electrical and chemical sei-
zure thresholds [95]. In line with these data, the efficacy of
5-CT against convulsions produced by picrotoxin was
blocked by SB-269970 [96]. Thus, data appear inconsistent
as to whether an activation or blockade of 5-HT7Rs will
produce antiepileptic activity.
11 Other Implications
The ligands of 5-HT7Rs may also be considered as a pos-
sible novel therapeutic target in autism spectrum disorders
(discussed in detail by Ciranna and Catania [97]). Key
evidence comes from a study demonstrating that 5-HT7R
activation by LP-211 corrected excessive metabotropic
glutamate receptor-mediated LTD in Fmr1KO mice, a
model of Fragile X Syndrome also considered as an animal
model of autism [98].
Recently, LP-211 was demonstrated to improve Rett
Syndrome-related defective performance, including the
anxiety-related profile, motor abilities and memory, in a
mouse genetic model of the disease [99].
It has also been demonstrated that the activation of
5-HT7Rs is responsible for serotonin-evoked cranial va-
sodilatation, which is considered to be one of the
mechanisms involved in migraines. Accordingly, the
5-HT7R antagonist SB-269970 inhibited the 5-CT-induced
dilatation in the middle meningeal artery in rats [100]. SB-
269970 also reduced neurogenic dural vasodilation evoked
by electrical stimulation of dura mater, whereas the
5-HT7R agonist AS19 increased it [101].
Preclinical studies have demonstrated the involvement
of 5-HT7R in the modulation of impulsivity [102], arousal
[46] and novelty-seeking behaviour [60, 61, 103]. Thus,
possible links to attention-deficit hyperactivity disorder
may also be suggested.
Finally, the involvement of 5-HT7Rs in processes that
contribute to the development and maintenance of addic-
tive behaviours may suggest a potential role for these re-
ceptors in alcohol and drug dependence (reviewed in detail
by Hauser et al. [104]).
12 Summary
Evidence supports the role for the 5-HT7R in a wide range
of pathological processes. Nevertheless, only one published
study has been designed to assess the clinical efficacy of a
5-HT7R antagonist, JNJ-18038683, in patients with de-
pression [16]. Unfortunately, this clinical trial was reported
as a failed study lacking assay sensitivity due to a high
placebo response. Some examples of the utility of 5-HT7R
blockade may be clinically effective drugs such as
amisulpride, lurasidone or vortioxetine that are charac-
terised by having significant affinity for 5-HT7R [23, 29,
30].
One may notice the heterogeneous results regarding the
effects of both antagonists and agonists of 5-HT7Rs, which
may hamper the clinical validation of the ligands of this
receptor. For example 5-HT7R antagonists exhibit an
antidepressant-like activity, but REM sleep suppression
may be induced by either agonists or antagonists of those
receptors [38]. Moreover, both agonists and antagonists
may exert anxiolytic-like effects [25, 46]. Similarly,
5-HT7R is necessary for hippocampal-dependent functions
[55], and the activation of this receptor reversed memory
deficits on a hippocampal-dependent task in a mouse model
of Rett syndrome [99]. On the other hand, antagonists of
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5-HT7Rs may be beneficial in treating schizophrenia-like
cognitive impairments [77, 83]. This may stem from
technical reasons like the use of unselective 5-HT agonists
or a low efficacy of available compounds, as, for example,
AS19 [50]. Moreover, dual agonist/antagonist properties
were reported for LP-211 [105]. It has also been suggested
that 5-HT7R-mediated signalling does not fit a two-state
activation/blockade model [38]. The role of the 5-HT7R
may depend on the brain region [38] and neurochemical
environment (e.g. serotonin level) [69] and may differ
between physiological and pathological conditions [91].
Moreover, alternative signalling pathways and homo/
heterodimerisations reveal a complex picture of the
5-HT7R [106, 107]. Of note is also the concept of so called
biased agonism or functional selectivity at GPCRs, which
implies that different ligands can activate distinct sig-
nalling pathways and differentially regulate desensitiza-
tion, internalization, down-regulation and dimerization
processes [108]. It is possible that biased agonism may
explain differential effects between different 5-HT7R
antagonists/agonists and even similar effects shared
between agonists and antagonists [10, 109]. Thus, further
studies are necessary to extend our knowledge of the
5-HT7Rs and therapeutic potential of their ligands.
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